1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics in the United States, January 2019 (p4)

Healthcare Analysis & Statistics in the United States, January 2019 (p4)

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Pharma Intelligence

All regions

data types

91-120 of about 300 reports

Zydelig

Zydelig

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewZydelig (idelalisib; Gilead) is an oral, highly selective inhibitor of the phosphoinositide 3-kinase (PI3K) isoform p110-delta. In vitro studies have demonstrated that Zydelig results in decreased ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
Kymriah

Kymriah

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewKymriah (tisagenlecleucel; Novartis) is a cluster of differentiation (CD)19-targeted genetically modified autologous T-cell immunotherapy, comprised of a murine single-chain antibody fragment ...

  • Industries : Cancer, Pathology, Medical Biotechnology
  • Countries : United States, European Union, Japan
Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia (CLL)

  • $ 22000
  • Industry report
  • January 2019

Disease OverviewChronic lymphocytic leukemia (CLL) is a disease characterized by an accumulation of mature malignant B lymphocytes in the peripheral blood, bone marrow, and lymph nodes. Diagnosis of CLL ...

  • Industries : Healthcare
  • Countries : United States, European Union, Japan
Gazyva

Gazyva

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewGazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) is a third-generation, type II glycoengineered, humanized anti-CD20 monoclonal antibody (MAb) that recognizes the type II epitope ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, European Union, Japan
Aliqopa

Aliqopa

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewAliqopa (copanlisib; Bayer) is a small molecule phosphoinositide 3-kinase (PI3K) inhibitor with high selectivity for the p110-alpha/delta catalytic subunits. The PI3K pathway is crucial fo ...

  • Industries : Cancer, Pathology, Therapy
  • Countries : United States, Japan, European Union
Venclexta

Venclexta

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewVenclexta (venetoclax; AbbVie/Roche) is an inhibitor of the B-cell lymphoma-2 (BCL-2) family of proteins. This family of proteins is responsible for the regulation of cell death by eithe ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Rituxan

Rituxan

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewRituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo) is a murine/human chimeric cluster of differentiation (CD)20-targeted monoclonal antibody that is indicated for the treatment of a numbe ...

  • Industries : Cancer, Pathology, Medical Biotechnology
  • Countries : United States, European Union, Japan
Treanda/Bendeka

Treanda/Bendeka

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewTreanda (bendamustine; Teva/Mundipharma/Eisai) is an intravenous cytotoxic agent. The exact mechanism of action of the drug is still not fully known, but it is a mechlorethamine derivative ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Ublituximab

Ublituximab

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewUblituximab (TG Therapeutics/LFB Biotechnologies) is an anti-CD20 monoclonal antibody, currently in late-stage trials across a range of hematological and neurological indications. CD20 is ...

  • Industries : Cancer, Pathology, Therapy
  • Countries : United States, European Union
Betalutin

Betalutin

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewBetalutin is a first-in-class antibody-radionucleotide conjugate targeted to CD37, an alternative to CD20, which is widely targeted in non-Hodgkin’s lymphoma. CD37 is highly expressed in ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026

NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026

  • $ 22000
  • Industry report
  • January 2019

Disease OverviewFollicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL). It is the second most common type of NHL after diffuse large B-cell lymphoma (DLBCL), and accounts fo ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Revlimid

Revlimid

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewRevlimid (lenalidomide; Celgene) is an oral thalidomide analog with antineoplastic, immunomodulatory, and anti-angiogenic properties. Studies have shown that Revlimid inhibits the growth of ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Zevalin

Zevalin

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewZevalin (ibritumomab tiuxetan; Acrotech Biopharma/Mundipharma) is an intravenous radioactive agent consisting of the murine monoclonal antibody (MAb) ibritumomab, which is covalently linked ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Europe, Japan
lisocabtagene maraleucel

lisocabtagene maraleucel

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewLisocabtagene maraleucel (also known as JCAR017; Celgene) will be the third autologous chimeric antigen receptor T-cell (CAR-T) therapy to reach the diffuse large B-cell lymphoma (DLBCL) market ...

  • Industries : Cancer, Medical Biotechnology, Pathology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Market Spotlight: Neuropathic Pain, Pharma Intelligence

Market Spotlight: Neuropathic Pain, Pharma Intelligence

  • $ 1318
  • Industry report
  • January 2019

This Market Spotlight report covers the neuropathic pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming events, probability of success, ...

  • Industries : Chronic Disease, Pathology
  • Countries : World, United States
umbralisib

umbralisib

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewUmbralisib (TG Therapeutics/Rhizen) is a novel phosphoinositide 3-kinase (PI3K) delta inhibitor that also selectively inhibits casein kinase-1 (CK1) epsilon. Expression of the PI3K delta isoform ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
Yescarta

Yescarta

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewYescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained ...

  • Industries : Medical Biotechnology, Cancer, Pathology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Alzheimer’s Disease KOL Interview – US, South

Alzheimer’s Disease KOL Interview – US, South

  • $ 599
  • Industry report
  • January 2019

OverviewThis interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. ...

  • Industries : Mental Health
  • Countries : United States
Alzheimer’s Disease KOL Interview – US, Northeast

Alzheimer’s Disease KOL Interview – US, Northeast

  • $ 599
  • Industry report
  • January 2019

OverviewThis interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. ...

  • Industries : Mental Health
  • Countries : United States
HIV Disease Coverage Forecast and Market Analysis to 2024, Pharma Intelligence

HIV Disease Coverage Forecast and Market Analysis to 2024, Pharma Intelligence

  • $ 22000
  • Industry report
  • January 2019

Disease OverviewThe human immunodeficiency virus, or HIV, is a retrovirus that infects the cells of the immune system such as T lymphocytes, specifically cluster of differentiation-4+ T cells, dendritic ...

  • Industries : Pathology
  • Countries : United States, European Union
Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026

Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026

  • $ 22000
  • Industry report
  • January 2019

DISEASE OVERVIEWChronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. In 2004, it was the fourth most common cause of death in the world, and it is projected ...

  • Industries : Healthcare
  • Countries : European Union, United States, Japan
Datamonitor Healthcare Multiple Myeloma KOL Interview – Midwestern, US

Datamonitor Healthcare Multiple Myeloma KOL Interview – Midwestern, US

  • $ 599
  • Industry report
  • January 2019

OverviewThis interview covers the current treatment of multiple myeloma in the UK, and the main areas of unmet need. Looking forward, we discuss the likely uptake of recently approved regimens, as well ...

  • Industries : Cancer
  • Countries : United States, United Kingdom
Fluad QIV

Fluad QIV

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewFluad QIV (CSL) is a subunit, surface antigen-containing seasonal quadrivalent influenza vaccine adjuvanted with MF-59, an oil-in-water emulsion. It contains antigens from two A strains and ...

  • Industries : Therapy
  • Countries : United States, European Union
FluMist QIV

FluMist QIV

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewFluMist QIV (AstraZeneca/Daiichi Sankyo) is a quadrivalent live-attenuated influenza vaccine containing antigens from two A strains and two B strains specified by the World Health Organization ...

  • Industries : Therapy
  • Countries : United States, European Union
Fluzone High-Dose

Fluzone High-Dose

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewFluzone HD (inactivated split virion; Sanofi Pasteur) is an inactivated influenza vaccine that contains antigens from two A strains and one B strain specified by the World Health Organization ...

  • Industries : Therapy
  • Countries : United States
Seasonal Influenza Vaccines

Seasonal Influenza Vaccines

  • $ 22000
  • Industry report
  • January 2019

DISEASE OVERVIEWSeasonal influenza is an acute viral infection that is spread by person-to-person transmission. Influenza, commonly referred to as the flu, circulates worldwide and can affect anyone in ...

  • Industries : Pathology, Therapy
  • Countries : United States, European Union
Flucelvax QIV

Flucelvax QIV

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewFlucelvax (subunit cell-based quadrivalent influenza vaccine; CSL) is an inactivated subunit cell-based quadrivalent influenza vaccine that contains antigens from two A strains and two B strains ...

  • Industries : Therapy
  • Countries : United States
Flublok

Flublok

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewFlublok (Sanofi) is a quadrivalent recombinant seasonal influenza vaccine that contains antigens from two A strains and two B strains specified by the World Health Organization seasonally ...

  • Industries : Therapy
  • Countries : United States
Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, Midwest

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, Midwest

  • $ 599
  • Industry report
  • January 2019

OverviewA US key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.Major marketed drugs ...

  • Industries : Cancer, Pathology
  • Countries : United States
Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, West Coast

Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, West Coast

  • $ 599
  • Industry report
  • January 2019

OverviewA US key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.Major marketed drugs ...

  • Industries : Cancer, Pathology
  • Countries : United States

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on